Platelets Function and Cardiovascular Events in Patients With End Stage Renal Disease
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00407368|
Recruitment Status : Unknown
Verified November 2006 by Assaf-Harofeh Medical Center.
Recruitment status was: Recruiting
First Posted : December 5, 2006
Last Update Posted : December 5, 2006
The purpose of this study is to perform a prospective evaluation regarding the relationship between platelets function and cardiovascular events in patients with ESRD.
The study will include 100-200 patients with ESRD, age 18 years or older, treated in the nephrology division of Assaf Harofeh medical center.
The primary end points of the study are cardiovascular events including acute myocardial infarction (defined as symptoms + acute elevation of TnI), need for coronary artery disease revascularization, or acute cerebrovascular event (TIA or CVA) and mortality. The secondary end points are any hospitalization due to acute coronary syndrome, active bleeding with the need for blood transfusion and dialysis access graft thrombosis (time to thrombosis).
Blood will be taken for complete blood count including platelets count and mean platelets volume, serum electrolytes, albumin, blood lipids, Kt/V, troponin and two 5 ml aliquots from each blood collection will be separated and stored at -70co until analyzed for oxidative stress, homocysteine and highly sensitive CRP will be performed. Five mL of blood will be sent for platelets function assessment.
During the follow up period the correlation between platelets function an cardiovascular events will be assessed.
|Condition or disease||Intervention/treatment|
|End Stage Renal Disease Cardiovascular Disease||Procedure: Blood Sample|
Show Detailed Description
|Study Type :||Observational|
|Enrollment :||150 participants|
|Observational Model:||Defined Population|
|Study Start Date :||September 2006|
|Study Completion Date :||December 2007|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00407368
|Contact: Shai Efrati, MDemail@example.com|
|Nephrology Division, Aassaf-Harofeh Medical Center||Recruiting|
|Zerifin, Israel, 70300|
|Contact: Shai Efrati, MD +972-577-346364 firstname.lastname@example.org|
|Principal Investigator: Mark Katz, MD|
|Study Chair:||Shai Efrati, MD||Assaf-Harofeh Medical Center|
|Principal Investigator:||Mark Katz, MD||Assaf-Harofeh Medical Center|